CVRx Q2 revenue beats estimates, outlook cut on sales force, payer challenges

CVRx lowered its full-year revenue outlook, citing sales force issues and challenges with a large payer.

The company now expects full-year 2026 revenue between $58 million and $60 million. It sees third-quarter 2026 revenue between $13.5 million and $14.5 million. CVRx also expects 2026 gross margin of 86% to 87% and operating expenses of $99 million to $101 million.

The current average analyst rating on the shares is "buy". The breakdown of recommendations is 6 "strong buy" or "buy", no "hold", and 1 "sell" or "strong sell".

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy". Wall Street's median 12-month price target for CVRx, Inc. is $12.00, about 115.1% above its August 5 closing price of $5.58.

CVRx said second-quarter revenue rose 16% year over year, beating analyst expectations. The medical device maker reported Q2 revenue of , compared with consensus estimates of from seven analysts.